Drug Approval | June 14, 2024
Farxiga approved in the US for the treatment of paediatric type-2 diabetes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Subscribe To Our Newsletter & Stay Updated
